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Sir,
We read with interest the article by Reyes et al (1999) describing a
transient suppression of lymphocyte proliferative response to
polyclonal mitogens in patients affected by breast cancer and
receiving rHuG-CSF to mobilize peripheral blood progenitor cells
(PBPC); these variations occurred irrespective of changes in both
T-cell subset distribution and lymphocyte ex vivo ‘activation
status’, as measured by expression of HLA-DR and CD25
activation-related antigens.
Data reported by Reyes et al confirm that G-CSF treatment
modulates the proliferative response of peripheral blood mono-
nuclear cells to T-cell mitogens in humans. Investigations
performed by our group in healthy subjects treated with rHuG-
CSF to mobilize PBPC have already demonstrated a humoral-
mediated rHuG-CSF-induced suppression of lymphocyte cycling
after mitogenic challenge (Rutella et al, 1997a; 1997b); interest-
ingly, lymphocyte proliferation inversely correlated with increased
serum levels of immunoregulatory cytokines, i.e. lactoferrin and
interleukin-1 receptor antagonist (IL-1ra), strongly suggesting
indirect actions mediated by soluble factors; this hypothesis is
further supported by the observation that lymphocytes apparently
lack G-CSF receptors (Mellstedt et al, 1999; Hartung, 1999).
We next evaluated the effects of serum collected after
rHuG-CSF administration (G-serum) on the proliferation of
normal allogeneic lymphocytes (Rutella et al, 1998); when PHA-
challenge was performed in the presence of G-serum, lymphocyte
cycling was strongly inhibited in a concentration-dependent
manner and lymphocytes were arrested in a G0-like phase of the
cell cycle, although they up-regulated the expression of early
(CD69) and late activation related antigens (CD25, CD71 and
HLA-DR), enlarged into blasts and secreted normal amounts of
IL-2. Taken together, these features recapitulate the phenotype
known as lymphocyte partial activation, which consists of:
(1) preserved blast transformation, (2) preserved up-regulation of
activation-related antigens, i.e. CD69, CD25, CD71 and HLA-DR,
(3) preserved secretion of IL-2 and (4) inability to progress
through the cell cycle upon mitogenic stimulation. Lymphocyte
partial activation has been regarded as a fundamental mechanism
for tolerance induction in T-cell clones and might control the
amplification of the immune response (Sloan-Lancaster et al, 1994).
From our data (Rutella et al, 1999) and those by other groups
(Hartung, 1999), a new intriguing role of rHuG-CSF as an immune
suppressive agent has emerged. The modulation of immune
responses might be beneficial after the infusion of rHuG-
CSF-mobilized allogeneic PBPC; conceivably, similar incidence
and severity of acute graft versus host disease (GVHD), which has
been recently reported after allogeneic PBPC compared to bone
marrow transplantation, might be explained by a functional
alteration of lymphocytes exposed in vivo to rHuG-CSF.
Interestingly, recent studies in a murine allogeneic transplant
model demonstrated a G-CSF-induced T-cell polarization toward a
type-2 phenotype (Pan et al, 1999), leading to attenuated secretion
of inflammatory cytokines from Th2 CD4+ T-cells and to enhanced
graft-versus-leukaemia (GVL) activity from Tc2 CD8+ cytotoxic
T-lymphocytes (CTL); thus, G-CSF-primed T-cells might: (1)
possess a diminished capacity to induce severe acute GVHD and
(2) maintain GVL function and efficiently induce apoptosis of
leukemic targets through a perforin-dependent pathway.
Investigations are currently ongoing to analyse the regulation of
lymphocyte cell cycle machinery after exposure to rHuG-CSF
(manuscript in preparation). Whether immune dysfunction will
favourably impact on incidence of acute GVHD after allogeneic
PBPC transplantation remains to be demonstrated in large series of
patients.
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